sacituzumab govitecan
gilead sciences
['tropics-02', 'mbc', 'breast']
tropics-02 (presented by ) met its primary endpoint. pfs is 5.5 months for sacituzumab and 4 months for chemo in heavily pretreated patients with er+ metastatic breast cancer. between this and #db04 (tomorrow) - is this the beginning of #adc era for er+ mbc? #asco22 
#BreastCancer Chief Oncologist | Researcher | Executive Medical Director @BCMCancerCenter @StLukesHealthTX | Innovation | Access to care | Views are my own